New York State Teachers Retirement System Acquires 22,263 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

New York State Teachers Retirement System lifted its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 90.5% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 46,855 shares of the company's stock after buying an additional 22,263 shares during the period. New York State Teachers Retirement System owned approximately 0.08% of Protagonist Therapeutics worth $2,266,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in PTGX. GF Fund Management CO. LTD. acquired a new position in shares of Protagonist Therapeutics during the fourth quarter worth approximately $48,000. GAMMA Investing LLC boosted its position in shares of Protagonist Therapeutics by 153.3% during the first quarter. GAMMA Investing LLC now owns 1,203 shares of the company's stock worth $58,000 after buying an additional 728 shares during the period. Covestor Ltd boosted its position in shares of Protagonist Therapeutics by 5,200.0% during the fourth quarter. Covestor Ltd now owns 1,643 shares of the company's stock worth $63,000 after buying an additional 1,612 shares during the period. New Vernon Capital Holdings II LLC acquired a new position in shares of Protagonist Therapeutics during the fourth quarter worth approximately $118,000. Finally, Cibc World Markets Corp acquired a new position in shares of Protagonist Therapeutics during the fourth quarter worth approximately $211,000. 98.63% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

PTGX has been the subject of several analyst reports. Citigroup initiated coverage on Protagonist Therapeutics in a research report on Tuesday, June 17th. They set a "buy" rating and a $72.00 price objective for the company. HC Wainwright reiterated a "buy" rating and set a $80.00 price objective on shares of Protagonist Therapeutics in a research report on Tuesday, June 3rd. Wedbush reissued an "outperform" rating and set a $70.00 target price on shares of Protagonist Therapeutics in a report on Friday, March 28th. Finally, Wall Street Zen raised Protagonist Therapeutics from a "sell" rating to a "hold" rating in a report on Sunday, June 8th. Two analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $66.10.

Insider Buying and Selling at Protagonist Therapeutics

In other Protagonist Therapeutics news, CFO Asif Ali sold 1,756 shares of the business's stock in a transaction on Tuesday, April 22nd. The shares were sold at an average price of $46.00, for a total transaction of $80,776.00. Following the sale, the chief financial officer directly owned 61,065 shares of the company's stock, valued at $2,808,990. The trade was a 2.80% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Arturo Md Molina sold 10,000 shares of the business's stock in a transaction on Tuesday, June 10th. The shares were sold at an average price of $57.03, for a total transaction of $570,300.00. Following the sale, the insider directly owned 83,892 shares in the company, valued at approximately $4,784,360.76. This trade represents a 10.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.90% of the stock is owned by insiders.

Protagonist Therapeutics Stock Performance

Shares of NASDAQ PTGX traded up $0.17 during trading on Friday, hitting $53.00. The company had a trading volume of 752,675 shares, compared to its average volume of 841,483. The company has a market cap of $3.28 billion, a P/E ratio of 70.67 and a beta of 2.26. Protagonist Therapeutics, Inc. has a 52 week low of $32.50 and a 52 week high of $60.60. The business's 50-day moving average is $50.03 and its 200 day moving average is $45.02.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.31. The company had revenue of $28.32 million for the quarter, compared to analysts' expectations of $30.44 million. Protagonist Therapeutics had a return on equity of 9.22% and a net margin of 27.04%. On average, research analysts expect that Protagonist Therapeutics, Inc. will post 2.43 EPS for the current year.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.